Chuy’s Holdings, Inc. (NASDAQ:CHUY) Given Consensus Rating of “Hold” by Analysts
Shares of Chuy’s Holdings, Inc. (NASDAQ:CHUY – Get Free Report) have received an average recommendation of “Hold” from the nine research firms that are presently covering the company, Marketbeat Ratings reports. Five analysts have rated the stock with a hold recommendation and four have issued a buy recommendation on the company. The average 12-month target […]
More Stories
Eureka Resources Inc., Prior to Reverse Merger with Kore Mining (CVE:EUK) Stock Crosses Above Fifty Day Moving Average – Here’s What Happened
Eureka Resources Inc., Prior to Reverse Merger with Kore Mining Ltd. (CVE:EUK – Get Free Report)’s share price passed above...
Metals Acquisition Limited (ASX:MAC) Insider Michael (Mick) McMullen Buys 16,957 Shares of Stock
Metals Acquisition Limited (ASX:MAC – Get Free Report) insider Michael (Mick) McMullen bought 16,957 shares of Metals Acquisition stock in...
NanoVibronix (NASDAQ:NAOV) Enters into Securities Exchange AgreementOn January 7, 2025, NanoVibronix, Inc. filed an 8-K form with the Securities and Exchange Commission, disclosing its recent agreement with an institutional investor. The company ente
This article was generated by an automated content engine and was reviewed by a human editor prior to publication. For...
**Freddie Mac Appoints James Whitlinger as EVP & CFO**McLean, Va. – Freddie Mac (OTCQB: FMCC) has recently revealed the appointment of James Whitlinger as Executive Vice President and Chief Financial Officer (CFO), effective January 1, 2025. Whitling
* This article was generated by an automated content engine and was reviewed by a human editor prior to publication....
Oxbridge Re Holdings Reports Potential Underwriting Losses in Connection with Hurricanes Helene and Milton
Oxbridge Re Holdings Limited (NASDAQ: OXBR) recently disclosed potential underwriting losses in a Current Report on Form 8-K. The losses...
Stoke Therapeutics Prepares for Phase 3 Study of Zorevunersen for Dravet Syndrome
Stoke Therapeutics, Inc. (NASDAQ: STOK) recently announced plans to launch a Phase 3 study of zorevunersen, aiming to develop the...